HKEX Biotech Summit 2023

Nicolas Aguzin joined HKEX as Chief Executive Officer on 24 May 2021 from J.P. Morgan, where he was most recently Chief Executive Officer of J.P. Morgan’s International Private Bank. Mr Aguzin has been based in Hong Kong since 2012.

From 2013 to 2020, Mr Aguzin was CEO, J.P. Morgan, Asia Pacific where he was responsible for all the firm’s business across 17 markets. Mr Aguzin presided over some of the firm’s major expansion efforts during the period, including establishing itself in China as one of the few international financial institutions with a full range of services and capabilities; including a fully-owned locally incorporated commercial bank, a majority-owned securities company, an asset management company and a futures and options company. Concurrent with his Asia CEO role, Mr Aguzin also ran J.P. Morgan’s Investment Banking division in Asia. During his tenure the bank rose to become one of the leading investment banks in the Asia Pacific region.

Mr Aguzin joined J.P. Morgan in 1990 in Buenos Aires as a financial analyst. Between 1990 and 2005, he held a variety of roles in New York and Buenos Aires, and in 2005 he was appointed as CEO, Latin America. In 2008 and 2009, in addition to his responsibilities as CEO, Latin America and Head of Latin America Investment Banking, he served as Senior Country Officer for Brazil.

Nicolas Aguzin joined HKEX as Chief Executive Officer on 24 May 2021 from J.P. Morgan, where he was most recently Chief Executive Officer of J.P. Morgan’s International Private Bank. Mr Aguzin has been based in Hong Kong since 2012.

From 2013 to 2020, Mr Aguzin was CEO, J.P. Morgan, Asia Pacific where he was responsible for all the firm’s business across 17 markets. Mr Aguzin presided over some of the firm’s major expansion efforts during the period, including establishing itself in China as one of the few international financial institutions with a full range of services and capabilities; including a fully-owned locally incorporated commercial bank, a majority-owned securities company, an asset management company and a futures and options company. Concurrent with his Asia CEO role, Mr Aguzin also ran J.P. Morgan’s Investment Banking division in Asia. During his tenure the bank rose to become one of the leading investment banks in the Asia Pacific region.

Mr Aguzin joined J.P. Morgan in 1990 in Buenos Aires as a financial analyst. Between 1990 and 2005, he held a variety of roles in New York and Buenos Aires, and in 2005 he was appointed as CEO, Latin America. In 2008 and 2009, in addition to his responsibilities as CEO, Latin America and Head of Latin America Investment Banking, he served as Senior Country Officer for Brazil.

Mr Philip Yung joined the Administrative Service in July 1986. He was Commissioner for Tourism from February 2010 to December 2014, Permanent Secretary for Commerce and Economic Development (Commerce, Industry and Tourism) from December 2014 to April 2018 and Permanent Secretary for Food and Health (Food) in April 2018. He has taken up the post of Director-General for Office for Attracting Strategic Enterprises since December 2022. 

Mr Philip Yung joined the Administrative Service in July 1986. He was Commissioner for Tourism from February 2010 to December 2014, Permanent Secretary for Commerce and Economic Development (Commerce, Industry and Tourism) from December 2014 to April 2018 and Permanent Secretary for Food and Health (Food) in April 2018. He has taken up the post of Director-General for Office for Attracting Strategic Enterprises since December 2022. 

Wilfred is Co‐Chief Operating Officer & Head of Equities of Hong Kong Exchanges and Clearing Limited (HKEX). He is also Chief Executive of HKEX’s wholly‐owned subsidiaries, The Stock Exchange of Hong Kong Limited and Hong Kong Futures Exchange Limited.

Previously, he was Deputy Chief Executive Officer and Chief Operating Officer for Beijing Gao Hua Securities Company Limited, and Chairman of its wholly‐owned subsidiary, Qian Kun Futures Co Ltd. Prior to that, he was Head of Credit Structured Products for Asia at Goldman Sachs (Asia) L.L.C. Mr Yiu served as a governor for the board of the Dalian Commodity Exchange in China from 2015 to 2017. Mr Yiu is a member of the Securities Compensation Fund Committee of the Securities and Futures Commission, and a member of Education and Development Committee of the Hong Kong Securities and Investment Institute. He is also a member of the Supervisory Committee for the Tracker Fund of Hong Kong.

Mr Yiu is an adjunct professor at the Hong Kong Polytechnic University. He is also an advisory board member of Research Institute for Business of The Hang Seng University of Hong Kong, and Professional Fellow of the Honours Academy of the Hang Seng University of Hong Kong.

Mr Yiu earned a Master’s degree in Computer Science from Stanford University and an MBA in Finance from the Stern School of Business at New York University.

Wilfred is Co‐Chief Operating Officer & Head of Equities of Hong Kong Exchanges and Clearing Limited (HKEX). He is also Chief Executive of HKEX’s wholly‐owned subsidiaries, The Stock Exchange of Hong Kong Limited and Hong Kong Futures Exchange Limited.

Previously, he was Deputy Chief Executive Officer and Chief Operating Officer for Beijing Gao Hua Securities Company Limited, and Chairman of its wholly‐owned subsidiary, Qian Kun Futures Co Ltd. Prior to that, he was Head of Credit Structured Products for Asia at Goldman Sachs (Asia) L.L.C. Mr Yiu served as a governor for the board of the Dalian Commodity Exchange in China from 2015 to 2017. Mr Yiu is a member of the Securities Compensation Fund Committee of the Securities and Futures Commission, and a member of Education and Development Committee of the Hong Kong Securities and Investment Institute. He is also a member of the Supervisory Committee for the Tracker Fund of Hong Kong.

Mr Yiu is an adjunct professor at the Hong Kong Polytechnic University. He is also an advisory board member of Research Institute for Business of The Hang Seng University of Hong Kong, and Professional Fellow of the Honours Academy of the Hang Seng University of Hong Kong.

Mr Yiu earned a Master’s degree in Computer Science from Stanford University and an MBA in Finance from the Stern School of Business at New York University.

Professor Lo has extensive experience in biotechnology industry, corporate management, academic research and community service. Currently Professor Lo is serving as the President of HK Bio-Med Innotech Association, Strategic Advisor to the President and Adjunct Professor to the Division of Life Science of Hong Kong University of Science and Technology. He is also the Honorary Founding Chairman of Hong Kong Biotechnology Organization. In the educational area, Professor Lo has been elected an Honorary Fellow of the Hong Kong University of Science and Technology. He is also the Honorary Professor of several universities in China. Professor Lo was heavily involved in several committees of the HKSAR Government. He had been served as the Chairman of the Advisory Council for Food Safety of the Food and Health Bureau HKSAR, Director of the Hong Kong Applied R&D Fund Co. Ltd., Chairman of the Biotechnology Committee of the Hong Kong Industry & Technology Development Council, and Chairman of Biotechnology Projects Vetting Committee of the Innovation and Technology Fund, HKSAR. In Mainland China, Professor Lo was a member of Chinese People’s Political Consultative Conference in Jilin Province from 2007 to 2022. He was also a consultant of the Centre for Disease Control and Prevention of China. In recognition of his leadership in the community and dedication to his field, Professor Lo has received many awards, such as the “Pericles International Prize” in 2019. He is the second Asian and the first person from Hong Kong to be awarded the Prize since it was founded in 1986. In 2020, Professor Lo was awarded the Bronze Bauhinia Star from the HKSAR government for his outstanding services over the past decades. In the business sector, Professor Lo had been served as the Chairman of Asia Pacific of PerkinEImer (NYSE: PKI) and the President of Asia Pacific of Bio-Rad Laboratories (NYSE: BIO). Currently he is the Chairman of GT Healthcare Capital Partners, and Partner & Investment Committee Member of Hongsen Investment Management Limited. 

Professor Lo has extensive experience in biotechnology industry, corporate management, academic research and community service. Currently Professor Lo is serving as the President of HK Bio-Med Innotech Association, Strategic Advisor to the President and Adjunct Professor to the Division of Life Science of Hong Kong University of Science and Technology. He is also the Honorary Founding Chairman of Hong Kong Biotechnology Organization. In the educational area, Professor Lo has been elected an Honorary Fellow of the Hong Kong University of Science and Technology. He is also the Honorary Professor of several universities in China. Professor Lo was heavily involved in several committees of the HKSAR Government. He had been served as the Chairman of the Advisory Council for Food Safety of the Food and Health Bureau HKSAR, Director of the Hong Kong Applied R&D Fund Co. Ltd., Chairman of the Biotechnology Committee of the Hong Kong Industry & Technology Development Council, and Chairman of Biotechnology Projects Vetting Committee of the Innovation and Technology Fund, HKSAR. In Mainland China, Professor Lo was a member of Chinese People’s Political Consultative Conference in Jilin Province from 2007 to 2022. He was also a consultant of the Centre for Disease Control and Prevention of China. In recognition of his leadership in the community and dedication to his field, Professor Lo has received many awards, such as the “Pericles International Prize” in 2019. He is the second Asian and the first person from Hong Kong to be awarded the Prize since it was founded in 1986. In 2020, Professor Lo was awarded the Bronze Bauhinia Star from the HKSAR government for his outstanding services over the past decades. In the business sector, Professor Lo had been served as the Chairman of Asia Pacific of PerkinEImer (NYSE: PKI) and the President of Asia Pacific of Bio-Rad Laboratories (NYSE: BIO). Currently he is the Chairman of GT Healthcare Capital Partners, and Partner & Investment Committee Member of Hongsen Investment Management Limited. 

Mr. Song Ruilin, Executive President of China Pharmaceutical Innovation and Research Development Association (PhIRDA), Expert of Talent Pool for State Affairs of Chinese People's Political Consultative Conference (CPPCC), Advisor on Participation in and Deliberation of State Affairs for the Central Committee of Chinese Peasants and Workers Democratic Party, Chairman of iMeta Health Information Consulting Co., Ltd. He is also L.L.B. of China University of Political Science and Law, EMBA of China Europe International Business School, Doctor of Social and Administrative Pharmacy of China Pharmaceutical University and Visiting Scholar of the University of Sydney. Mr. Song had served in the Legislative Affairs Office at State Council of China for a long time, engaging in health and drug policy, legal studies and in charge of law making and reviewing in the areas of pharmaceutical and healthcare industry. In recent years, he mainly engages in the research on China's pharmaceutical innovation policy.

Currently, Mr. Song also undertakes several social positions, such as Executive Deputy Director of the Research Center of National Drug Policy & Ecosystem of China Pharmaceutical University, Visiting Research Fellow of Shanghai Jiao Tong University, Member of TCM Strategic Expert Consultation Committee of NMPA, Biotech Advisory Panel Member of the SEHK, Vice President of China Alliance for Rare Disease (CARD), Honorary Director of Chinese Pharmaceutical Association (CPA), Director of Chinese Pharmacists Association and Director of Bethune Charitable Foundation.

Mr. Song Ruilin, Executive President of China Pharmaceutical Innovation and Research Development Association (PhIRDA), Expert of Talent Pool for State Affairs of Chinese People's Political Consultative Conference (CPPCC), Advisor on Participation in and Deliberation of State Affairs for the Central Committee of Chinese Peasants and Workers Democratic Party, Chairman of iMeta Health Information Consulting Co., Ltd. He is also L.L.B. of China University of Political Science and Law, EMBA of China Europe International Business School, Doctor of Social and Administrative Pharmacy of China Pharmaceutical University and Visiting Scholar of the University of Sydney. Mr. Song had served in the Legislative Affairs Office at State Council of China for a long time, engaging in health and drug policy, legal studies and in charge of law making and reviewing in the areas of pharmaceutical and healthcare industry. In recent years, he mainly engages in the research on China's pharmaceutical innovation policy.

Currently, Mr. Song also undertakes several social positions, such as Executive Deputy Director of the Research Center of National Drug Policy & Ecosystem of China Pharmaceutical University, Visiting Research Fellow of Shanghai Jiao Tong University, Member of TCM Strategic Expert Consultation Committee of NMPA, Biotech Advisory Panel Member of the SEHK, Vice President of China Alliance for Rare Disease (CARD), Honorary Director of Chinese Pharmaceutical Association (CPA), Director of Chinese Pharmacists Association and Director of Bethune Charitable Foundation.

Christina Bao, Managing Director, is currently the Co-Head of Sales & Marketing at HKEX. 

Ms Bao joined HKEX in 2016 as the Chief of Staff, reporting to the CE of HKEX. She was responsible for the planning and oversight of the Group’s strategic projects.

Prior to joining HKEX, Ms Bao held a number of senior positions at Ping An Bank (previously at Shenzhen Development Bank, which merged with Ping An Bank in 2010) since 2001. At Shenzhen Development Bank, she served as the Chief of Staff to the Chairman and CEO from 2005 until 2010, and was responsible for the bank’s strategic projects, Investor Relations and Public Relations. After the merger and integration of the two banks, she headed Retail e-Banking, Service & Marketing, and the Retail e-Finance Strategic Business Unit for Ping An Bank.

Ms Bao received her Master of Business Administration (Finance, General) from the Peking University of Mainland China.

Christina Bao, Managing Director, is currently the Co-Head of Sales & Marketing at HKEX. 

Ms Bao joined HKEX in 2016 as the Chief of Staff, reporting to the CE of HKEX. She was responsible for the planning and oversight of the Group’s strategic projects.

Prior to joining HKEX, Ms Bao held a number of senior positions at Ping An Bank (previously at Shenzhen Development Bank, which merged with Ping An Bank in 2010) since 2001. At Shenzhen Development Bank, she served as the Chief of Staff to the Chairman and CEO from 2005 until 2010, and was responsible for the bank’s strategic projects, Investor Relations and Public Relations. After the merger and integration of the two banks, she headed Retail e-Banking, Service & Marketing, and the Retail e-Finance Strategic Business Unit for Ping An Bank.

Ms Bao received her Master of Business Administration (Finance, General) from the Peking University of Mainland China.

Dr Karen Atkin is the Executive Vice President and Chief Operating Officer of HUTCHMED. Prior to joining the Company in 2021, Dr Atkin spent 24 years at AstraZeneca in senior medical, regulatory, pharmacovigilance, R&D and commercial leadership roles, including as senior vice president of medical for biopharmaceuticals, vice president of the global infection, neuroscience and autoimmunity therapy area and the established brand business, country president of Indonesia and led China R&D for over four years. Dr Atkin is also a registered physician with advanced level qualifications in internal medicine and pharmaceutical medicine. Dr Atkin holds three Bachelor’s degrees in Physiology, Medicine and Surgery, respectively, from University College London. She graduated with a First Class Honors degree in Medicine, holds a Master of Business Administration from the Open University, is a member of the Royal College of Physicians and a fellow of the Faculty of Pharmaceutical Medicine in the UK.

Dr Karen Atkin is the Executive Vice President and Chief Operating Officer of HUTCHMED. Prior to joining the Company in 2021, Dr Atkin spent 24 years at AstraZeneca in senior medical, regulatory, pharmacovigilance, R&D and commercial leadership roles, including as senior vice president of medical for biopharmaceuticals, vice president of the global infection, neuroscience and autoimmunity therapy area and the established brand business, country president of Indonesia and led China R&D for over four years. Dr Atkin is also a registered physician with advanced level qualifications in internal medicine and pharmaceutical medicine. Dr Atkin holds three Bachelor’s degrees in Physiology, Medicine and Surgery, respectively, from University College London. She graduated with a First Class Honors degree in Medicine, holds a Master of Business Administration from the Open University, is a member of the Royal College of Physicians and a fellow of the Faculty of Pharmaceutical Medicine in the UK.

Dr. Zhang Fangliang is the co-founder and an executive Director of Genscript Biotech Corporation. He is also a director and chairman of Legend Biotech Corporation.

Dr. Zhang has over 25 years of experience in the biotechnology industry. Prior to joining the Group, from 1995 to 2002, he worked as a postdoctoral research fellow and an associate principal scientist at Schering-Plough. Dr. Zhang worked in the tumour biology department during his postdoctoral research at Schering-Plough. Dr. Zhang was also one of the key team members for an anti-cancer drug, farnesyl transferase inhibitor. After Dr. Zhang’s postdoctoral studies, he was recruited to the department of central nervous system and cardiovascular system at Schering-Plough. He became one of the project leaders focusing on G-protein coupled receptors and led a group of scientists to discover the drug target for a billion-dollar drug. As a result of this discovery, Dr. Zhang won a Presidential Award at Schering-Plough in 2001. From 2002 to August 2020, Dr. Zhang worked as the chief executive officer of GenScript, where he was involved in a variety of key biotechnological research projects and provided guidance and directions to those biotechnological research projects.

Dr. Zhang obtained a Bachelor of Engineering degree from Chengdu College of Geology* (成都地质学院) (currently known as Chengdu University of Technology* (成都理工大学)) in the PRC in July 1984 and a Master of Science degree from Nanjing University in the PRC in July 1987. He also obtained a Doctor of Biochemistry degree from Duke University in the U.S. in September 1995.

Dr. Zhang Fangliang is the co-founder and an executive Director of Genscript Biotech Corporation. He is also a director and chairman of Legend Biotech Corporation.

Dr. Zhang has over 25 years of experience in the biotechnology industry. Prior to joining the Group, from 1995 to 2002, he worked as a postdoctoral research fellow and an associate principal scientist at Schering-Plough. Dr. Zhang worked in the tumour biology department during his postdoctoral research at Schering-Plough. Dr. Zhang was also one of the key team members for an anti-cancer drug, farnesyl transferase inhibitor. After Dr. Zhang’s postdoctoral studies, he was recruited to the department of central nervous system and cardiovascular system at Schering-Plough. He became one of the project leaders focusing on G-protein coupled receptors and led a group of scientists to discover the drug target for a billion-dollar drug. As a result of this discovery, Dr. Zhang won a Presidential Award at Schering-Plough in 2001. From 2002 to August 2020, Dr. Zhang worked as the chief executive officer of GenScript, where he was involved in a variety of key biotechnological research projects and provided guidance and directions to those biotechnological research projects.

Dr. Zhang obtained a Bachelor of Engineering degree from Chengdu College of Geology* (成都地质学院) (currently known as Chengdu University of Technology* (成都理工大学)) in the PRC in July 1984 and a Master of Science degree from Nanjing University in the PRC in July 1987. He also obtained a Doctor of Biochemistry degree from Duke University in the U.S. in September 1995.

Dr Amit Kakar joined Novo Holdings Asia in August 2020 as Head of Asia to lead investments and partnerships across the region, focusing primarily on the markets in China, Southeast Asia and India. 

Dr Amit Kakar has more than 25 years of healthcare experience with several senior management roles across the globe and having worked in India, China, Singapore, Denmark and the USA. Previously, he has been with Everlife Asia based in Singapore as Head of M&A and Business Development, with the Avenue Capital Group as Head of healthcare investments for Asia and with GE Healthcare in several senior leadership positions.

Dr Amit Kakar is a Medical Doctor with a postgraduate degree in Radiation and Nuclear Medicine from Tata Memorial Hospital and Cancer Centre in Mumbai, India.

Dr Amit Kakar joined Novo Holdings Asia in August 2020 as Head of Asia to lead investments and partnerships across the region, focusing primarily on the markets in China, Southeast Asia and India. 

Dr Amit Kakar has more than 25 years of healthcare experience with several senior management roles across the globe and having worked in India, China, Singapore, Denmark and the USA. Previously, he has been with Everlife Asia based in Singapore as Head of M&A and Business Development, with the Avenue Capital Group as Head of healthcare investments for Asia and with GE Healthcare in several senior leadership positions.

Dr Amit Kakar is a Medical Doctor with a postgraduate degree in Radiation and Nuclear Medicine from Tata Memorial Hospital and Cancer Centre in Mumbai, India.

As a DPhil of Lanzhou University, Prof Zhang has engaged in R&D and industrialization of new viral vaccines, antibodies and immune diagnostic reagents for decades.

Prof Zhang participated in scientific research of COVID-19 vaccine, diagnostic and therapeutic products, and successfully acquired first pre qualification and EUL in WHO for COVID-19 inactivated vaccine in the world. Now the vaccine has been registered and released to 121 countries, regions and international organizations. The vaccinated population covers 196 countries. More than 3.5 billion doses of vaccines have been produced and distributed nationwide and overseas, which has made immense contributions to the control of pandemic.

Before Pandemic, Prof Zhang developed China's first new target vaccine for EV71, with a general protection rate of over 90% and a severe protection rate of 100%. After the vaccine was launched, the annual child mortality rate of EV71 in China decreased by 93.5%, which was highly recommended by WHO. He then promoted the research and industrialization of IPV, which filled in the blank of IPV market and passed WHO validation. The product quality has reached international criteria, facilitated China's combined vaccination scheme of bOPV and IPV, and contributed to global polio eradication strategy.

As an outstanding project lead, Prof Zhang undertook a number of major projects such as infectious disease project "New Hepatitis B Vaccine Development" of "Twelfth Five Year Plan", novel drug development project "Research on upgrading Technology and Quality Standards of Immunization Program and Vaccine Industry such as Component Cell-free DPT" of "Thirteenth Five Year Plan", novel drug development project "The Establishment and Application of all Human Monoclonal Antibody Drug Development Technology Platform", and promoted several trials of combined vaccines, monoclonal antibodies and world's first IL-17 Fc fusion protein.

Prof Zhang have also developed a number of diagnostic products, including SARS diagnostic reagent, hepatitis C virus Abzyme linked immunodiagnostic reagent, hepatitis C virus core antigen detection reagent, HIV (HIV-1/2) Abzyme linked immunodiagnostic kit, and rotavirus diagnostic kit (ELISA), which then obtained new drug certificates and production approval, etc.

Prof Zhang, as an owner of multiple patents, published over 60 articles in journals like Lancet, Cell, and JAMA. In 2022, the project "Development and Application of COVID-19 Inactivated Vaccine" lead by Prof Zhang, won the first prize of Beijing Science and Technology Progress Award, and the project "Development and Application of New Pandemic Vaccine, Construction and Application of Industrialized Technology System" won the first prize of Science and Technology Award of 17th Chinese Pharmaceutical Association. Also in 2022, he was awarded "the most Excellent Scientific and Technological Worker" in Beijing, "Outstanding Individual in Combating COVID-19" by Ministry of Science and Technology and State Owned Assets Supervision and Administration Commission.

Outside CNBG, Prof Zhang served as Biological Products Committee’s Deputy Director of Chinese Preventive Healthcare Association, Vaccine Professional Committee’s Deputy Director of Chinese Medical Biotechnology Association, Biological Products Professional Committee’s Deputy Director of Chinese Society of Microbiology, and Quality Committee’s Director of Chinese Vaccine Industry Association.

As a DPhil of Lanzhou University, Prof Zhang has engaged in R&D and industrialization of new viral vaccines, antibodies and immune diagnostic reagents for decades.

Prof Zhang participated in scientific research of COVID-19 vaccine, diagnostic and therapeutic products, and successfully acquired first pre qualification and EUL in WHO for COVID-19 inactivated vaccine in the world. Now the vaccine has been registered and released to 121 countries, regions and international organizations. The vaccinated population covers 196 countries. More than 3.5 billion doses of vaccines have been produced and distributed nationwide and overseas, which has made immense contributions to the control of pandemic.

Before Pandemic, Prof Zhang developed China's first new target vaccine for EV71, with a general protection rate of over 90% and a severe protection rate of 100%. After the vaccine was launched, the annual child mortality rate of EV71 in China decreased by 93.5%, which was highly recommended by WHO. He then promoted the research and industrialization of IPV, which filled in the blank of IPV market and passed WHO validation. The product quality has reached international criteria, facilitated China's combined vaccination scheme of bOPV and IPV, and contributed to global polio eradication strategy.

As an outstanding project lead, Prof Zhang undertook a number of major projects such as infectious disease project "New Hepatitis B Vaccine Development" of "Twelfth Five Year Plan", novel drug development project "Research on upgrading Technology and Quality Standards of Immunization Program and Vaccine Industry such as Component Cell-free DPT" of "Thirteenth Five Year Plan", novel drug development project "The Establishment and Application of all Human Monoclonal Antibody Drug Development Technology Platform", and promoted several trials of combined vaccines, monoclonal antibodies and world's first IL-17 Fc fusion protein.

Prof Zhang have also developed a number of diagnostic products, including SARS diagnostic reagent, hepatitis C virus Abzyme linked immunodiagnostic reagent, hepatitis C virus core antigen detection reagent, HIV (HIV-1/2) Abzyme linked immunodiagnostic kit, and rotavirus diagnostic kit (ELISA), which then obtained new drug certificates and production approval, etc.

Prof Zhang, as an owner of multiple patents, published over 60 articles in journals like Lancet, Cell, and JAMA. In 2022, the project "Development and Application of COVID-19 Inactivated Vaccine" lead by Prof Zhang, won the first prize of Beijing Science and Technology Progress Award, and the project "Development and Application of New Pandemic Vaccine, Construction and Application of Industrialized Technology System" won the first prize of Science and Technology Award of 17th Chinese Pharmaceutical Association. Also in 2022, he was awarded "the most Excellent Scientific and Technological Worker" in Beijing, "Outstanding Individual in Combating COVID-19" by Ministry of Science and Technology and State Owned Assets Supervision and Administration Commission.

Outside CNBG, Prof Zhang served as Biological Products Committee’s Deputy Director of Chinese Preventive Healthcare Association, Vaccine Professional Committee’s Deputy Director of Chinese Medical Biotechnology Association, Biological Products Professional Committee’s Deputy Director of Chinese Society of Microbiology, and Quality Committee’s Director of Chinese Vaccine Industry Association.

Ms. Katherine Ng is the Head of Listing at Hong Kong Exchanges and Clearing Limited (“HKEX”).  She joined HKEX in 2013 as the Head of Policy of the Listing Division. Ms. Ng has led the major listing policy initiatives in recent years, including the development and enhancements to the ESG regulatory framework, and represents HKEX in the Green and Sustainable Finance Cross-Agency Steering Group.  Prior to joining HKEX, Ms. Ng served as Political Assistant to the Secretary for Financial Services and the Treasury of the Hong Kong Government, worked in an international investment bank and an international law firm in Hong Kong and London.  Ms. Ng holds a Master of Arts in Law from Trinity College, University of Cambridge and is a qualified lawyer in both Hong Kong and England & Wales.  Ms. Ng is currently an Advisor to Our Hong Kong Foundation, a Director of the World Wide Fund for Nature Hong Kong, a fellow of the Aspen Institute, a Member of the Hong Kong Academy of Finance and a senior fellow of Hong Kong Securities and Investment Institute (“HKSI”).  She was a Director of HKSI from December 2014 to December 2022 and the Chairman between December 2018 to December 2021.

Ms. Katherine Ng is the Head of Listing at Hong Kong Exchanges and Clearing Limited (“HKEX”).  She joined HKEX in 2013 as the Head of Policy of the Listing Division. Ms. Ng has led the major listing policy initiatives in recent years, including the development and enhancements to the ESG regulatory framework, and represents HKEX in the Green and Sustainable Finance Cross-Agency Steering Group.  Prior to joining HKEX, Ms. Ng served as Political Assistant to the Secretary for Financial Services and the Treasury of the Hong Kong Government, worked in an international investment bank and an international law firm in Hong Kong and London.  Ms. Ng holds a Master of Arts in Law from Trinity College, University of Cambridge and is a qualified lawyer in both Hong Kong and England & Wales.  Ms. Ng is currently an Advisor to Our Hong Kong Foundation, a Director of the World Wide Fund for Nature Hong Kong, a fellow of the Aspen Institute, a Member of the Hong Kong Academy of Finance and a senior fellow of Hong Kong Securities and Investment Institute (“HKSI”).  She was a Director of HKSI from December 2014 to December 2022 and the Chairman between December 2018 to December 2021.

Stephanie Lau, is the Co-Head of IPO Vetting, Listing Division at the HKEX. Working in partnership with Ms. Li-Chien Wong, Ms. Lau will oversee all HKEX issuer listing applications and will lead a highly experienced team of professionals that support the continued development of Hong Kong as a global listing venue of choice.

Ms. Lau qualified as a lawyer in Hong Kong, as well as in England and Wales, and has over 20 years of experience in corporate finance and listing related matters. Ms. Lau also served as a Senior Vice President of Listed Issuer Regulation, Listing Division at the HKEX, prior to heading the IPO Vetting Department.

Stephanie Lau, is the Co-Head of IPO Vetting, Listing Division at the HKEX. Working in partnership with Ms. Li-Chien Wong, Ms. Lau will oversee all HKEX issuer listing applications and will lead a highly experienced team of professionals that support the continued development of Hong Kong as a global listing venue of choice.

Ms. Lau qualified as a lawyer in Hong Kong, as well as in England and Wales, and has over 20 years of experience in corporate finance and listing related matters. Ms. Lau also served as a Senior Vice President of Listed Issuer Regulation, Listing Division at the HKEX, prior to heading the IPO Vetting Department.

Li-Chien Wong, is the Co-Head of IPO Vetting, Listing Division at the HKEX. Together with Stephanie Lau, Ms. Wong will have oversight of all HKEX issuer listing applications.

Ms. Wong has over 25 years of experience in private practice as a corporate and capital markets lawyer, 20 of those in Hong Kong, having advised leading investment banks and a wide range of corporates on capital market matters.

Li-Chien Wong, is the Co-Head of IPO Vetting, Listing Division at the HKEX. Together with Stephanie Lau, Ms. Wong will have oversight of all HKEX issuer listing applications.

Ms. Wong has over 25 years of experience in private practice as a corporate and capital markets lawyer, 20 of those in Hong Kong, having advised leading investment banks and a wide range of corporates on capital market matters.

Dr. Patrick Lam is the Vice President of IPO Vetting, Listing Division at the HKEX, and has supported the Division with his corporate, academia, and entrepreneurial experiences with pharmaceuticals, biologics, medical devices and service providers of the health industries since the launch of the Biotech Chapter.

Prior to the HKEX and for more than a decade, Patrick was a senior management consultant in advisory practice most recently in Monitor Deloitte, and before that PwC Hong Kong and Greater China specializing in strategy & operations for private and public sector clients in Pharmaceuticals, Life Sciences and Healthcare areas. Patrick obtained his PhD (Physiology) and completed his Postgraduate Fellowship (Medicine) at the University of Toronto. 

Dr. Patrick Lam is the Vice President of IPO Vetting, Listing Division at the HKEX, and has supported the Division with his corporate, academia, and entrepreneurial experiences with pharmaceuticals, biologics, medical devices and service providers of the health industries since the launch of the Biotech Chapter.

Prior to the HKEX and for more than a decade, Patrick was a senior management consultant in advisory practice most recently in Monitor Deloitte, and before that PwC Hong Kong and Greater China specializing in strategy & operations for private and public sector clients in Pharmaceuticals, Life Sciences and Healthcare areas. Patrick obtained his PhD (Physiology) and completed his Postgraduate Fellowship (Medicine) at the University of Toronto. 

Vernon Tam is the Vice President of IPO Vetting, Listing Division at the HKEX. He has over 15 years of healthcare and corporate finance experience. He started his career in the pharmaceutical industry in MSD and Eli Lilly, and then worked in investment banks including Deutsche Bank and Bank of China International focusing on biotechnology and healthcare sector for more than 10 years.

Mr. Tam graduated from the University of Hong Kong with a Bachelor of Science in molecular biology and Master of Philosophy in reproductive endocrinology. He also holds an MBA degree from the Chinese University of Hong Kong and completed the international MBA program with a major in healthcare finance in Duke University.

Vernon Tam is the Vice President of IPO Vetting, Listing Division at the HKEX. He has over 15 years of healthcare and corporate finance experience. He started his career in the pharmaceutical industry in MSD and Eli Lilly, and then worked in investment banks including Deutsche Bank and Bank of China International focusing on biotechnology and healthcare sector for more than 10 years.

Mr. Tam graduated from the University of Hong Kong with a Bachelor of Science in molecular biology and Master of Philosophy in reproductive endocrinology. He also holds an MBA degree from the Chinese University of Hong Kong and completed the international MBA program with a major in healthcare finance in Duke University.

Dr. Carol Chan is an Assistant Vice President of IPO Vetting, Listing Division at the HKEX, with a main focus on vetting applications and pre-IPO enquiry under Chapter 18A. She has over 13 years of pharmaceutical and biomedical research experiences. She was responsible for the medical affairs in various drugs across different therapeutic areas in Gilead Sciences and GSK. She was a postdoctoral research follow in the York University and the University of British Columbia in Canada prior to joining the pharmaceutical industry in 2015. She has a PhD in microbiology and nutrition from the University of Hong Kong.

Dr. Carol Chan is an Assistant Vice President of IPO Vetting, Listing Division at the HKEX, with a main focus on vetting applications and pre-IPO enquiry under Chapter 18A. She has over 13 years of pharmaceutical and biomedical research experiences. She was responsible for the medical affairs in various drugs across different therapeutic areas in Gilead Sciences and GSK. She was a postdoctoral research follow in the York University and the University of British Columbia in Canada prior to joining the pharmaceutical industry in 2015. She has a PhD in microbiology and nutrition from the University of Hong Kong.

Winnie Han is the Head of China Issuer Services and Senior Vice President of Global Issuer Services in HKEX. Her key focus is to lead the China team to promote HKEX as the top listing venue for Greater China companies. She has extensive coverage and works closely with Chinese/Southeast Asian potential issuers, investors, governments, associations and intermediaries. She is a familiar face on many New Economy, Advanced Technology or Healthcare Forums/Summits/Conferences promoting Hong Kong as the Go-To IPO destination.

Prior to her current role, Ms Han had over 15 years of experiences in China A-share investment banking at UBS and Credit Suisse. Before joining HKEX, she was the Co-Head of ECM at Credit Suisse Founder Securities. She holds China A-share Sponsor Representatives Qualification and Certified Public Accountant Qualification of China (non-practicing).

Ms Han received her Master’s degree from Peking University and Bachelor’s degree from Xiamen University.

Winnie Han is the Head of China Issuer Services and Senior Vice President of Global Issuer Services in HKEX. Her key focus is to lead the China team to promote HKEX as the top listing venue for Greater China companies. She has extensive coverage and works closely with Chinese/Southeast Asian potential issuers, investors, governments, associations and intermediaries. She is a familiar face on many New Economy, Advanced Technology or Healthcare Forums/Summits/Conferences promoting Hong Kong as the Go-To IPO destination.

Prior to her current role, Ms Han had over 15 years of experiences in China A-share investment banking at UBS and Credit Suisse. Before joining HKEX, she was the Co-Head of ECM at Credit Suisse Founder Securities. She holds China A-share Sponsor Representatives Qualification and Certified Public Accountant Qualification of China (non-practicing).

Ms Han received her Master’s degree from Peking University and Bachelor’s degree from Xiamen University.

Dr. Qi Fei is currently serving as the Chief Strategy Officer at PT Etana Biotechnologies Indonesia, where he is responsible for strategic planning, financing, and business development. Dr. Qi Fei is also an Executive Director at Legend Capital, focusing on investments in cutting-edge biotechnology, digital healthcare, and cross-border expansion.

Dr. Qi holds a Ph. D. degree in cell biology and a bachelor degree in biotechnology from Peking University. Prior to joining Legend Capital, Dr. Qi worked as a visiting scholar at University of California, Los Angeles (UCLA).

Dr. Qi Fei is currently serving as the Chief Strategy Officer at PT Etana Biotechnologies Indonesia, where he is responsible for strategic planning, financing, and business development. Dr. Qi Fei is also an Executive Director at Legend Capital, focusing on investments in cutting-edge biotechnology, digital healthcare, and cross-border expansion.

Dr. Qi holds a Ph. D. degree in cell biology and a bachelor degree in biotechnology from Peking University. Prior to joining Legend Capital, Dr. Qi worked as a visiting scholar at University of California, Los Angeles (UCLA).

Xinyan Li, MD. Ph.D.,who is the Co-Founder, CEO and CMO of Frontera Therapeutics got her B.S. in immunology and Ph. D. in tumor immunology from Soochow University and was a visiting scholar at the Gene and Cell Therapy Center of Montpellier University, France.  Dr. Li had been working in the hospital as a physician for 5 years and also had 10 years of teaching and scientific research experience before she started her journey in the biopharmaceutical field as an overseas returnee. Dr.Li has been engaged in innovative drug R&D management for 20 years, including R&D, preclinical pharmacology/toxicology study,  clinical development, registration, GMP production of biological products, government relations, fund applications, etc.
      As the project leader, Dr. Li led the clinical trials of two innovative drugs in both China and U.S and gained valuable management experience in the field of innovative drug R&D. When she was the senior president at Carsgen, Dr. Li was in charge of multiple departments across the area of pre-clinical, IIT, clinical trial, and China and US registration of CAR T cell.

Xinyan Li, MD. Ph.D.,who is the Co-Founder, CEO and CMO of Frontera Therapeutics got her B.S. in immunology and Ph. D. in tumor immunology from Soochow University and was a visiting scholar at the Gene and Cell Therapy Center of Montpellier University, France.  Dr. Li had been working in the hospital as a physician for 5 years and also had 10 years of teaching and scientific research experience before she started her journey in the biopharmaceutical field as an overseas returnee. Dr.Li has been engaged in innovative drug R&D management for 20 years, including R&D, preclinical pharmacology/toxicology study,  clinical development, registration, GMP production of biological products, government relations, fund applications, etc.
      As the project leader, Dr. Li led the clinical trials of two innovative drugs in both China and U.S and gained valuable management experience in the field of innovative drug R&D. When she was the senior president at Carsgen, Dr. Li was in charge of multiple departments across the area of pre-clinical, IIT, clinical trial, and China and US registration of CAR T cell.

Xiaodong Tao, graduated from University of Science and Technology of China with a B.S. degree in Electrical Engineering. In 2005, he obtained his Ph.D. degree in Electrical and Computer Engineering from the Johns Hopkins University. Since then, he worked at General Electric Company and Royal Philips Electronics of the Netherlands, where he led teams working on research and development of cutting-edge technologies for healthcare and medical equipment, in particular, imaging devices, imaging methods, clinical applications, and radiology solutions. Dr. Tao joined iFLYTEK Health in Jan. 2017 as the CEO. Since 2021, he was appointed adjunct professor at the School of Biomedical Engineering at the University of Science and Technology of China.

Xiaodong Tao, graduated from University of Science and Technology of China with a B.S. degree in Electrical Engineering. In 2005, he obtained his Ph.D. degree in Electrical and Computer Engineering from the Johns Hopkins University. Since then, he worked at General Electric Company and Royal Philips Electronics of the Netherlands, where he led teams working on research and development of cutting-edge technologies for healthcare and medical equipment, in particular, imaging devices, imaging methods, clinical applications, and radiology solutions. Dr. Tao joined iFLYTEK Health in Jan. 2017 as the CEO. Since 2021, he was appointed adjunct professor at the School of Biomedical Engineering at the University of Science and Technology of China.

Mr. Yong Zhong currently serves as the Chairman of Jinxin Fuxing Eldercare Industry Group Company Limited and Jinxin Fertility Group Ltd. Additionally, he holds membership in the Sichuan Institute of Certified Public Accountants. He earned his undergraduate degree from Southwestern University of Finance & Economics and his graduate degree from Sichuan University.

Mr. Yong Zhong currently serves as the Chairman of Jinxin Fuxing Eldercare Industry Group Company Limited and Jinxin Fertility Group Ltd. Additionally, he holds membership in the Sichuan Institute of Certified Public Accountants. He earned his undergraduate degree from Southwestern University of Finance & Economics and his graduate degree from Sichuan University.

Mr. Fei Chen is the Executive Director and Chief Financial Officer of YSB Inc. since April 2022.

Prior to joining YSB, Mr. Chen previously worked as an investment banker with HSBC from 2008 to 2010, and with UBS from 2010 to 2018. From May 2018 to April 2022, Mr. Chen was the Chief Financial Officer and Board Secretary at Tubatu Group.

Mr. Chen received his bachelor’s degree in finance and master’s degree in finance from Peking University in China.

Mr. Fei Chen is the Executive Director and Chief Financial Officer of YSB Inc. since April 2022.

Prior to joining YSB, Mr. Chen previously worked as an investment banker with HSBC from 2008 to 2010, and with UBS from 2010 to 2018. From May 2018 to April 2022, Mr. Chen was the Chief Financial Officer and Board Secretary at Tubatu Group.

Mr. Chen received his bachelor’s degree in finance and master’s degree in finance from Peking University in China.

Mr. Barry Chan is a Managing Director and the Head of Investment Banking, Hong Kong of China International Capital Corporation Limited (“CICC”). Mr. Chan has been appointed as the Head of the Asia-Australia Region of CICC International, responsible for business development in the region under the internationalization strategy of the firm.

Mr. Chan has over 30 years experience in the securities and financial sectors in Hong Kong and Mainland China, including an 11-year experience as a securities regulator at Hong Kong Exchanges and Clearing Limited (“HKEx”). Since joining CICC in September 2010, Mr. Chan has been responsible for developing CICC’s investment banking business in Hong Kong and overseas. He led the team to complete the IPOs and other capital market transactions for many SOEs, privately-owned Chinese enterprises, and international and local corporations. Before joining CICC, Mr. Chan was a senior member of the Listing Division of the HKEx and a member of the Mainland – Hong Kong Joint Working Group on Financial Affairs.

Mr. Chan obtained a bachelor’s degree in business administration and a master's degree in science from the Chinese University of Hong Kong. Mr. Chan is also a qualified accountant.

Mr. Barry Chan is a Managing Director and the Head of Investment Banking, Hong Kong of China International Capital Corporation Limited (“CICC”). Mr. Chan has been appointed as the Head of the Asia-Australia Region of CICC International, responsible for business development in the region under the internationalization strategy of the firm.

Mr. Chan has over 30 years experience in the securities and financial sectors in Hong Kong and Mainland China, including an 11-year experience as a securities regulator at Hong Kong Exchanges and Clearing Limited (“HKEx”). Since joining CICC in September 2010, Mr. Chan has been responsible for developing CICC’s investment banking business in Hong Kong and overseas. He led the team to complete the IPOs and other capital market transactions for many SOEs, privately-owned Chinese enterprises, and international and local corporations. Before joining CICC, Mr. Chan was a senior member of the Listing Division of the HKEx and a member of the Mainland – Hong Kong Joint Working Group on Financial Affairs.

Mr. Chan obtained a bachelor’s degree in business administration and a master's degree in science from the Chinese University of Hong Kong. Mr. Chan is also a qualified accountant.

Dr. Jane Zheng is the Co-founder and CEO of Belief BioMed. Prior to joining Belief BioMed, she served as Associate Professor at the East China University of Science and Technology's School of Pharmacy, was a Partner at Genechem, and was the Co-founder and CEO of Neuron Biotech.
For more than 20 years, Dr. Zheng has been dedicated to innovative research and to the clinical transformation of gene therapy technology, during which time she has accumulated extensive practical experience and expertise. She has led and participated in multiple national and municipal scientific research projects, published over 30 articles in Science Citation Index (SCI) journals, and over the past five years received a dozen awards, presented by industry, government, and media, including Forbes Women in Tech 2022 and Endpoints 20 of the Top Women Leading Biopharma R&D 2023.
In 2018, Dr. Zheng co-founded Belief BioMed, a high-tech company that engages in the research and development, production, and clinical application of gene therapy products. Under her leadership, the company has successfully raised hundreds of millions of dollars in four rounds of financing, built a hefty pipeline of gene therapy programs, and completed IND submission and clinical validation for gene therapies in various therapeutical areas.
In addition to her corporate responsibilities, Dr. Zheng also holds several administrative positions, including acting as a reviewer for the Ministry of Industry and Information Technology, serving as a member of the fifteenth Xuhui Political Consultative Congress, serving as a delegate of the sixth People's Congress of Meilong Town, Minhang District, and acting as a graduate supervisor in pharmacy at East China University of Science and Technology.
Dr. Zheng received a Ph.D. in Neurobiology from the Institute of Neuroscience, Chinese Academy of Sciences, and holds a Bachelor's Degree in Biochemistry and Molecular Biology from Nankai University.

Dr. Jane Zheng is the Co-founder and CEO of Belief BioMed. Prior to joining Belief BioMed, she served as Associate Professor at the East China University of Science and Technology's School of Pharmacy, was a Partner at Genechem, and was the Co-founder and CEO of Neuron Biotech.
For more than 20 years, Dr. Zheng has been dedicated to innovative research and to the clinical transformation of gene therapy technology, during which time she has accumulated extensive practical experience and expertise. She has led and participated in multiple national and municipal scientific research projects, published over 30 articles in Science Citation Index (SCI) journals, and over the past five years received a dozen awards, presented by industry, government, and media, including Forbes Women in Tech 2022 and Endpoints 20 of the Top Women Leading Biopharma R&D 2023.
In 2018, Dr. Zheng co-founded Belief BioMed, a high-tech company that engages in the research and development, production, and clinical application of gene therapy products. Under her leadership, the company has successfully raised hundreds of millions of dollars in four rounds of financing, built a hefty pipeline of gene therapy programs, and completed IND submission and clinical validation for gene therapies in various therapeutical areas.
In addition to her corporate responsibilities, Dr. Zheng also holds several administrative positions, including acting as a reviewer for the Ministry of Industry and Information Technology, serving as a member of the fifteenth Xuhui Political Consultative Congress, serving as a delegate of the sixth People's Congress of Meilong Town, Minhang District, and acting as a graduate supervisor in pharmacy at East China University of Science and Technology.
Dr. Zheng received a Ph.D. in Neurobiology from the Institute of Neuroscience, Chinese Academy of Sciences, and holds a Bachelor's Degree in Biochemistry and Molecular Biology from Nankai University.

Dr. Bo Ying has dedicated over a decade of his career to the technology research into nucleic acid -based therapeutics and the development of transformative drugs. He founded Abogen, a biotechnology company with a mission of curing otherwise untreatable diseases through mRNA science and technology. As the founder, Dr Ying also has served as Chairman of the board and CEO of Abogen. Under his leadership, the company has established its own proprietary mRNA platform and delivery technology that allowed the development of the therapeutics and vaccines for infectious diseases, cancer, and rare diseases. Most recently, Abogen’s mRNA platform capabilities have come together to allow the authorized use and approval of first China made mRNA vaccine against the COVID-19 pandemic. Prior to founding Abogen, Dr Ying had held several roles at numerous leading biopharmaceutical and biotechnologies companies in the US, mainly responsible for leading drug formulation, process development, technology transfer and manufacturing. Across his career, he takes pride in a broad array of innovative drug developing experiences in siRNA, mRNA-based therapies for tumor immunotherapy, cancer vaccines and gene-editing drug product candidates. Dr. Ying received his bachelor’s degree in life sciences from Fudan University, Shanghai, and Ph.D. in pharmaceutical sciences from Northeastern University. He is credited as the inventor of a dozen issued patents and patent applications, and his work appears in journals such as Cell and Lancet. Over the years, Dr. Ying has held several positions in influential organizations. From 2018 to 2019, he served as the president of the Chinese-American BioMedical Association (CABA) in Boston, where he made contributions to the advancement of science and technological innovation with great potential to improve human health.

Dr. Bo Ying has dedicated over a decade of his career to the technology research into nucleic acid -based therapeutics and the development of transformative drugs. He founded Abogen, a biotechnology company with a mission of curing otherwise untreatable diseases through mRNA science and technology. As the founder, Dr Ying also has served as Chairman of the board and CEO of Abogen. Under his leadership, the company has established its own proprietary mRNA platform and delivery technology that allowed the development of the therapeutics and vaccines for infectious diseases, cancer, and rare diseases. Most recently, Abogen’s mRNA platform capabilities have come together to allow the authorized use and approval of first China made mRNA vaccine against the COVID-19 pandemic. Prior to founding Abogen, Dr Ying had held several roles at numerous leading biopharmaceutical and biotechnologies companies in the US, mainly responsible for leading drug formulation, process development, technology transfer and manufacturing. Across his career, he takes pride in a broad array of innovative drug developing experiences in siRNA, mRNA-based therapies for tumor immunotherapy, cancer vaccines and gene-editing drug product candidates. Dr. Ying received his bachelor’s degree in life sciences from Fudan University, Shanghai, and Ph.D. in pharmaceutical sciences from Northeastern University. He is credited as the inventor of a dozen issued patents and patent applications, and his work appears in journals such as Cell and Lancet. Over the years, Dr. Ying has held several positions in influential organizations. From 2018 to 2019, he served as the president of the Chinese-American BioMedical Association (CABA) in Boston, where he made contributions to the advancement of science and technological innovation with great potential to improve human health.

Dr. Lu Yang brings over 25 years of experience in nucleic serial entrepreneurship, management, scientific knowledge in drug acid drug development, and rich preclinical experience. He founded and has led Sirnaomics from an early discovery startup to a siRNA therapeutics product company, with multiple programs currently at the clinical stage.

Prior to establishing the Group, Dr. Lu served as a lab head and senior scientist at Genetic Therapy, Inc., a Novartis company in the U.S., and worked at Digene Corporation in the U.S., Dr. Lu co-founded Intradigm Corp. in the U.S. and served as the executive vice president and led research and development until January 2007.

Dr. Lu obtained a bachelor’s degree in biology, a master’s degree, and a doctoral degree in botany from Sun Yat-sen University. He also conducted postdoctoral research in molecular genetics at the University of Maryland at College Park and was awarded a National Science Foundation Postdoctoral Fellowship Grant, and postdoctoral research in cancer at Georgetown University Medical Center.

Dr. Lu Yang brings over 25 years of experience in nucleic serial entrepreneurship, management, scientific knowledge in drug acid drug development, and rich preclinical experience. He founded and has led Sirnaomics from an early discovery startup to a siRNA therapeutics product company, with multiple programs currently at the clinical stage.

Prior to establishing the Group, Dr. Lu served as a lab head and senior scientist at Genetic Therapy, Inc., a Novartis company in the U.S., and worked at Digene Corporation in the U.S., Dr. Lu co-founded Intradigm Corp. in the U.S. and served as the executive vice president and led research and development until January 2007.

Dr. Lu obtained a bachelor’s degree in biology, a master’s degree, and a doctoral degree in botany from Sun Yat-sen University. He also conducted postdoctoral research in molecular genetics at the University of Maryland at College Park and was awarded a National Science Foundation Postdoctoral Fellowship Grant, and postdoctoral research in cancer at Georgetown University Medical Center.

Sandy Mou serves as Board Executive Director and Chief Executive Officer at JIXING. She is responsible for leading the full scope of business operations of the company.
Sandy Mou has nearly 30 years of experience in the pharmaceutical and medical device industry in China and has held management positions at several multinational pharmaceutical companies including GSK, AstraZeneca, Xi’an Janssen, Johnson & Johnson Medical and MSD. She has led teams to successfully launch several leading brands covering a wide range of therapeutic areas including cardiovascular and metabolic diseases, orthopedics, immunology and oncology. In May 2017, Sandy joined MSD China to establish the oncology business unit and oversaw several product launches including Keytruda. Under her leadership, the MSD China’s oncology business was ranked among the top three oncology businesses of multinational pharmaceutical companies in China after just three years. In March 2020, Sandy joined Shanghai Allist Pharmaceutical Technology Co. (Allist) as the Chief Executive Officer. During her tenure, Allist was successfully listed on the Science and Technology Board of the Shanghai Stock Exchange, achieved the first new drug approval, commercial launch and listing in the National Reimbursement Drug List. Under Sandy’s leadership, Allist has completed the transformation from a biotech company to an innovative biopharmaceutical company with integrated R&D, manufacturing and commercialization capabilities and has achieved profitability.
Sandy graduated from Shanghai Medical College of Fudan University with a bachelor's degree in Medicine and worked as a clinician for 7 years after graduation. Sandy also holds an EMBA degree from China Europe International Business School.

Sandy Mou serves as Board Executive Director and Chief Executive Officer at JIXING. She is responsible for leading the full scope of business operations of the company.
Sandy Mou has nearly 30 years of experience in the pharmaceutical and medical device industry in China and has held management positions at several multinational pharmaceutical companies including GSK, AstraZeneca, Xi’an Janssen, Johnson & Johnson Medical and MSD. She has led teams to successfully launch several leading brands covering a wide range of therapeutic areas including cardiovascular and metabolic diseases, orthopedics, immunology and oncology. In May 2017, Sandy joined MSD China to establish the oncology business unit and oversaw several product launches including Keytruda. Under her leadership, the MSD China’s oncology business was ranked among the top three oncology businesses of multinational pharmaceutical companies in China after just three years. In March 2020, Sandy joined Shanghai Allist Pharmaceutical Technology Co. (Allist) as the Chief Executive Officer. During her tenure, Allist was successfully listed on the Science and Technology Board of the Shanghai Stock Exchange, achieved the first new drug approval, commercial launch and listing in the National Reimbursement Drug List. Under Sandy’s leadership, Allist has completed the transformation from a biotech company to an innovative biopharmaceutical company with integrated R&D, manufacturing and commercialization capabilities and has achieved profitability.
Sandy graduated from Shanghai Medical College of Fudan University with a bachelor's degree in Medicine and worked as a clinician for 7 years after graduation. Sandy also holds an EMBA degree from China Europe International Business School.

Dr. Xiangyang Tan brings close to 30 years of biopharmaceutical industry experience and scientific and managerial roles in the discovery and development of biological therapeutics. He has contributed to efforts that have led to the delivery of numerous preclinical and clinical candidates in a range of disease areas, such as oncology, inflammatory and autoimmune disorders, and neurological diseases at global pharmaceutical companies, such as Wyeth, Pfizer, Biogen，Abpro and Harbour Biomed. At 2021, Dr. Tan joined Kelun-Biotech and was appointed as CSO in charge of preclinical research and development of innovative medicines.
Prior to joining the biopharmaceutical industry, Dr. Tan completed his postdoctoral training from Harvard Medical School. He has a scientific track record with over 40 research papers published in leading scientific journals including PNAS, Nature, Circulation, J Immunology, J Exp Med. He also contributed to over 30 US and international patents.
Dr. Tan holds a MD degree from Harbin Medical University, China, and a PhD degree in Cell and Molecular Biology from Manchester Met University, UK.

Dr. Xiangyang Tan brings close to 30 years of biopharmaceutical industry experience and scientific and managerial roles in the discovery and development of biological therapeutics. He has contributed to efforts that have led to the delivery of numerous preclinical and clinical candidates in a range of disease areas, such as oncology, inflammatory and autoimmune disorders, and neurological diseases at global pharmaceutical companies, such as Wyeth, Pfizer, Biogen，Abpro and Harbour Biomed. At 2021, Dr. Tan joined Kelun-Biotech and was appointed as CSO in charge of preclinical research and development of innovative medicines.
Prior to joining the biopharmaceutical industry, Dr. Tan completed his postdoctoral training from Harvard Medical School. He has a scientific track record with over 40 research papers published in leading scientific journals including PNAS, Nature, Circulation, J Immunology, J Exp Med. He also contributed to over 30 US and international patents.
Dr. Tan holds a MD degree from Harbin Medical University, China, and a PhD degree in Cell and Molecular Biology from Manchester Met University, UK.

Mr. Da LIU’s first traditional Chinese book, “Life Science Investments – Capturing the Next Unicorn” (“生命科技投资启示录 - 捕捉下一只独角兽”) was launched in November 2021 by the Commercial Press (Hong Kong). It was awarded with Hong Kong Publishing Biennial Awards 2023 in Business and Management sector by the Hong Kong Publishing Professionals Society Ltd in June 2023. His English publication, “Life Sciences Unicorns – From a China Investment Perspective” was launched in June 2023 by the Commercial Press (Singapore). This is the first in Hong Kong that systematically explores China’s life sciences investment from a global perspective.

Mr. Liu is one of the founding Managing Directors of CR-CP Life Science Fund, where he spearheaded a number of successful investments in the life science industry, including Legend Biotech (LEGN.US), New Horizon Health (06606.HK), JW Therapeutics (02126.HK), Sirnaomics (02257.HK), Transcenta (06628.HK) and MiRXES. He started as a Clinical Pharmacist in New York city, later worked with CVS as a Pharmacy Manager.  Upon returning to Beijing in 2004, Mr. Liu was the Deputy General Manager for Beijing Pharmaceutical. He later expanded his responsibilities in areas such as business development, supply chain, pharmacy retail, medical devices, as well as sales and marketing. Mr. Liu was Head of Business Development with China Resources Pharmaceutical Group Limited (03320.HK).

Mr. Da Liu is dedicated in contributing to the life sciences ecosystem of Hong Kong and the Greater Bay Area: he serves as an advisor to the Committee on Innovation, Technology and Industry Development under the Innovation, Technology and Industry Bureau of Hong Kong SAR Government.

Mr. Da LIU’s first traditional Chinese book, “Life Science Investments – Capturing the Next Unicorn” (“生命科技投资启示录 - 捕捉下一只独角兽”) was launched in November 2021 by the Commercial Press (Hong Kong). It was awarded with Hong Kong Publishing Biennial Awards 2023 in Business and Management sector by the Hong Kong Publishing Professionals Society Ltd in June 2023. His English publication, “Life Sciences Unicorns – From a China Investment Perspective” was launched in June 2023 by the Commercial Press (Singapore). This is the first in Hong Kong that systematically explores China’s life sciences investment from a global perspective.

Mr. Liu is one of the founding Managing Directors of CR-CP Life Science Fund, where he spearheaded a number of successful investments in the life science industry, including Legend Biotech (LEGN.US), New Horizon Health (06606.HK), JW Therapeutics (02126.HK), Sirnaomics (02257.HK), Transcenta (06628.HK) and MiRXES. He started as a Clinical Pharmacist in New York city, later worked with CVS as a Pharmacy Manager.  Upon returning to Beijing in 2004, Mr. Liu was the Deputy General Manager for Beijing Pharmaceutical. He later expanded his responsibilities in areas such as business development, supply chain, pharmacy retail, medical devices, as well as sales and marketing. Mr. Liu was Head of Business Development with China Resources Pharmaceutical Group Limited (03320.HK).

Mr. Da Liu is dedicated in contributing to the life sciences ecosystem of Hong Kong and the Greater Bay Area: he serves as an advisor to the Committee on Innovation, Technology and Industry Development under the Innovation, Technology and Industry Bureau of Hong Kong SAR Government.

Yi Wang is the Managing Director and Head of Quantitative Investment at CSOP Asset Management Ltd. He oversees all ETF product investment activities including Equity ETFs, Leveraged and Inverse ETPs, Money Market Fund ETFs and Fixed Income ETFs. He also oversees the active Fixed Income portfolio management. He is the voting member within CSOP investment committee and deputy chairman of CSOP responsible investment committee. Prior Joining CSOP, Yi was in Redington LLP (London) focusing on UK and EU pension/insurance investment solution. He graduated from University College of London with a major in Mathematics and CASS Business School with master’s degree in Actuarial Science.

Yi Wang is the Managing Director and Head of Quantitative Investment at CSOP Asset Management Ltd. He oversees all ETF product investment activities including Equity ETFs, Leveraged and Inverse ETPs, Money Market Fund ETFs and Fixed Income ETFs. He also oversees the active Fixed Income portfolio management. He is the voting member within CSOP investment committee and deputy chairman of CSOP responsible investment committee. Prior Joining CSOP, Yi was in Redington LLP (London) focusing on UK and EU pension/insurance investment solution. He graduated from University College of London with a major in Mathematics and CASS Business School with master’s degree in Actuarial Science.

Brian is Managing Director, Head of Equities Product Development. In this capacity, Brian oversees the development and management of HKEX’s equities products, focusing on market development, client engagement and investor education. Brian joined in 2015 bringing over 10 years of ETF development and leadership experience to HKEX. Prior to HKEX, Brian was at Vanguard, where he was most recently Head of ETF Product Development Asia, focusing on developing their global ETF business. Brian holds an undergraduate degree from Purdue University and an MBA from Thunderbird School of Global Management.

Brian is Managing Director, Head of Equities Product Development. In this capacity, Brian oversees the development and management of HKEX’s equities products, focusing on market development, client engagement and investor education. Brian joined in 2015 bringing over 10 years of ETF development and leadership experience to HKEX. Prior to HKEX, Brian was at Vanguard, where he was most recently Head of ETF Product Development Asia, focusing on developing their global ETF business. Brian holds an undergraduate degree from Purdue University and an MBA from Thunderbird School of Global Management.

Before joining Hang Seng Indexes Company in 2022, Danny Chu was a Greater China telecom analyst at a multinational investment bank covering telecom service providers and telecom equipment companies. His research team was ranked multiple times in Institutional Investor All-Asia Research Team (Telecommunications category), in which his research team was ranked #1 consecutively for three years in a row for 2011 to 2013. In 1999, he received his Master of Business Administration degree from University of Michigan at which he majored in finance. In 1993, he earned his Bachelor of Arts in Business Administration degree from University of Washington at which he majored in accounting. Danny is also a Chartered Financial Analyst.

Before joining Hang Seng Indexes Company in 2022, Danny Chu was a Greater China telecom analyst at a multinational investment bank covering telecom service providers and telecom equipment companies. His research team was ranked multiple times in Institutional Investor All-Asia Research Team (Telecommunications category), in which his research team was ranked #1 consecutively for three years in a row for 2011 to 2013. In 1999, he received his Master of Business Administration degree from University of Michigan at which he majored in finance. In 1993, he earned his Bachelor of Arts in Business Administration degree from University of Washington at which he majored in accounting. Danny is also a Chartered Financial Analyst.

Christopher Lui is a Managing Director at Jefferies leading the firm’s Asia (ex. Japan ex. Australia) healthcare equity research efforts. He has 15+ years of experience covering Greater China and ASEAN healthcare in bulge bracket and regional investment banks. He has participated in and led 30+ healthcare IPOs in HK and US. He also worked in a global healthcare specialist fund prior to joining Jefferies. Christopher has a BSc in Biochemistry and BSc in Mathematical Economics from the University of Wisconsin - Madison.

Christopher Lui is a Managing Director at Jefferies leading the firm’s Asia (ex. Japan ex. Australia) healthcare equity research efforts. He has 15+ years of experience covering Greater China and ASEAN healthcare in bulge bracket and regional investment banks. He has participated in and led 30+ healthcare IPOs in HK and US. He also worked in a global healthcare specialist fund prior to joining Jefferies. Christopher has a BSc in Biochemistry and BSc in Mathematical Economics from the University of Wisconsin - Madison.

Cui is a member of the Global Emerging Markets and Asia Pacific Equities team and is responsible for investment analysis of China/Hong Kong equities, specificized in healthcare sector.

Cui joined UBS Global Asset Management in May 2021. Prior to this, she was the Head of China Healthcare Research in Citigroup Global Markets Asia, where she led the team and ranked No. 1 in the Institutional Investor All Asia Research Poll in 2017 - 2021. Cui worked at Citi for 6 years.

Her previous experience includes healthcare equity research at Macquarie and CICC, as well as R&D at Johnson&Johnson Emerging Market Innovation Center.

Cui has a Bachelor degree in Science, majoring in Biological Sciences, from Fudan University. In addition, she has a Masters degree in Science, majoring in International Finance from Università Commerciale Luigi Bocconi in Italy. She was also an exchange scholar at Yale University, School of Medicine.

Cui is a member of the Global Emerging Markets and Asia Pacific Equities team and is responsible for investment analysis of China/Hong Kong equities, specificized in healthcare sector.

Cui joined UBS Global Asset Management in May 2021. Prior to this, she was the Head of China Healthcare Research in Citigroup Global Markets Asia, where she led the team and ranked No. 1 in the Institutional Investor All Asia Research Poll in 2017 - 2021. Cui worked at Citi for 6 years.

Her previous experience includes healthcare equity research at Macquarie and CICC, as well as R&D at Johnson&Johnson Emerging Market Innovation Center.

Cui has a Bachelor degree in Science, majoring in Biological Sciences, from Fudan University. In addition, she has a Masters degree in Science, majoring in International Finance from Università Commerciale Luigi Bocconi in Italy. She was also an exchange scholar at Yale University, School of Medicine.